scholarly journals Transcatheter Closure of Patent Ductus Arteriosus in Premature Infants With Very Low Birth Weight

2021 ◽  
Vol 8 ◽  
Author(s):  
Jieh-Neng Wang ◽  
Yung-Chieh Lin ◽  
Min-Ling Hsieh ◽  
Yu-Jen Wei ◽  
Ying-Tzu Ju ◽  
...  

Background: The aim of this study was to describe our experience with transcatheter device closure of patent ductus arteriosus (PDA) in symptomatic low-birth-weight premature infants.Methods: We performed a retrospective study of infants born with a birth body weight of < 2,000 g and admitted to National Cheng Kung University Hospital from September 2014 to December 2019. Basic demographic and clinical information as well as echocardiographic and angiographic data were recorded.Results: Twenty-five premature infants (11 boys and 14 girls) born at gestational ages ranging between 22 and 35 weeks (mean, 25 weeks) were identified. The mean age at procedure was 34.5 ± 5.5 days, and the mean weight was 1,209 ± 94 g (range, 478–1,980 g). The mean diameter of the PDA was 3.4 ± 0.2 mm (range, 2.0–5.4 mm). The following devices were used in this study: Amplatzer Ductal Occluder II additional size (n = 20), Amplatzer Vascular Plug I (n = 1), and Amplatzer Vascular Plug II (n = 4). Complete closure was achieved in all patients. The mean follow-up period was 30.1 ± 17.3 months (range, 6–68 months). In total, 3 patients had left pulmonary artery (LPA) stenosis and 1 patient had coarctation of the aorta during the follow-up period. Younger procedure age and smaller procedure body weight were significantly associated with these obstructions.Conclusions: Performing transcatheter PDA closure in symptomatic premature infants weighing more than 478 g is feasible using currently available devices; moreover, the procedure serves as an alternative to surgery.

2020 ◽  
Vol 61 (4) ◽  
pp. 399-405
Author(s):  
Hasan F. Othman ◽  
Debra T. Linfield ◽  
Mohamed A. Mohamed ◽  
Hany Aly

Author(s):  
Elizabeth E. LaSalle ◽  
Carolyn M. Wilhelm ◽  
Renelle S. George ◽  
Mohammad Shahnewaz Khan ◽  
Vidhi Shah ◽  
...  

2014 ◽  
Vol 7 ◽  
pp. OJCS.S20358
Author(s):  
Gökhan Albayrak ◽  
Koray Aykut ◽  
Mustafa Karacelik ◽  
Ramazan Soylar ◽  
Kemal Karaarslan ◽  
...  

2017 ◽  
Vol 34 (13) ◽  
pp. 1312-1317 ◽  
Author(s):  
Cuneyt Tayman ◽  
Ufuk Cakır ◽  
Mehmet Buyuktiryaki ◽  
Utku Serkant ◽  
Serife Oğuz ◽  
...  

Background Diagnosis and treatment of patent ductus arteriosus (PDA) in premature infants is still an important problem for clinicians. Echocardiography is the gold standard for determination of PDA based on clinical and hemodynamic significance. Clinical decision making may be aided by measuring circulating biomarkers such as natriuretic and endothelial propeptides. We aimed to investigate the significance of serum endocan and B-type natriuretic peptide (BNP) in the diagnosis and follow-up of hemodynamically significant PDA (hsPDA) in very low birth weight infants. Materials and Methods In this study, 84 premature infants with gestation age less than 32 weeks were included. Forty-two premature infants with hsPDA were determined as the study group and 42 premature infants without PDA were assigned as the control group. Blood samples were collected and analyzed for serum endocan and pro-BNP levels. Results Serum levels of pro-BNP and endocan in the study group at the time of diagnosis of PDA were found to be significantly higher than the control group, and the levels decreased significantly after medication. Multivariate regression analysis showed that birth weight and the presence of PDA were significantly correlated with serum endocan levels. The cutoff values of pro-BNP and endocan for PDA prediction were 290 pg/mL and 506 ng/mL, respectively. Conclusion Endocan and pro-BNP assays have clinical importance in the diagnosis, initiation therapy, and follow response to therapy in very low birth weight infants with hsPDA.


Sign in / Sign up

Export Citation Format

Share Document